title: Effect of Rowatinex on calculus clearance after extracorporeal shock wave lithotripsy.
abstract: BACKGROUND
  our aim was to evaluate the effect of Rowatinex, an essential oil preparation of terpenic type, on kidney calculi clearance after extracorporeal shock wave lithotripsy (SWL).
  
  
  METHODS
  A randomized controlled trial was performed at Hormozgan Hospital in Bandar Abbas, Iran, on 100 patients with 10-mm to 20-mm kidney calculi. They underwent SWL, and then, they were randomly assigned into 2 groups to receive either Rowatinex, 100 mg, 3 times per day, or placebo after SWL. Patients were followed up with plain abdominal radiography, ultrasonography, and excretory urography (if required), 2 and 4 weeks postoperatively.
  
  
  RESULTS
  Two weeks following SWL, 6 (12%) and 9 (18%) patients in the Rowatinex and control groups had fragmented calculi without clearance, 26 (52%) and 24 (48%) had less than 50% clearance, 9 (18%) and 15 (30%) had more than 50% but not total clearance, and 9 (18%) and 2 (4%) patients were stone free, respectively. Rowatinex had a significant effect on the stone-free rate (P = .02). Four weeks post-SWL, 3 (7.3%) and 7 (14.6%) other patients in the Rowatinex and control groups became stone free, respectively. Overall, Rowatinex had no significant effect on the stone-free rate (P = .46). No complications or differences between the two groups in symptoms and signs were reported.
  
  
  CONCLUSIONS
  Rowatinex does not have a significant effect on clearance rate of kidney calculi after SWL. However, it can accelerate calculus passage after 2 weeks, and it does not have any significant adverse effects.
authors.affiliation: Department of Urology, Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. hoomanj@hums.ac.ir
authors.forename: Hooman
authors.initials: H
authors.lastname: Djaladat
authors.forename: Khatereh
authors.initials: K
authors.lastname: Mahouri
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Khalifeh Shooshtary
authors.forename: Azadeh
authors.initials: A
authors.lastname: Ahmadieh
mesh_terms: D000328:Adult; D015331:Cohort Studies; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007492:Iran; D007669:Kidney Calculi / Q000628:therapy*; D008096:Lithotripsy; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D016037:Single-Blind Method; D013729:Terpenes / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D013729:Terpenes; C036965:Rowatinex